Synergistic blockade of mitotic exit by two chemical inhibitors of the APC/C
Open accessAbstract
Protein machines are multi-subunit protein complexes that orchestrate highly regulated biochemical tasks. An example is the anaphase-promoting complex/cyclosome (APC/C), a 13-subunit ubiquitin ligase that initiates the metaphase-anaphase transition and mitotic exit by targeting proteins such as securin and cyclin B1 for ubiquitin-dependent destruction by the proteasome. Because blocking mitotic exit is an effective approach for inducing tumour cell death, the APC/C represents a potential novel target for cancer therapy. APC/C activation in mitosis requires binding of Cdc20 (ref. 5), which forms a co-receptor with the APC/C to recognize substrates containing a destruction box (D-box). Here we demonstrate that we can synergistically inhibit APC/C-dependent proteolysis and mitotic exit by simultaneously disrupting two protein-protein interactions within the APC/C-Cdc20-substrate ternary complex. We identify a small molecule, called apcin (APC inhibitor), which binds to Cdc20 and competitively inhibits the ubiquitylation of D-box-containing substrates. Analysis of the crystal structure of the apcin-Cdc20 complex suggests that apcin occupies the D-box-binding pocket on the side face of the WD40-domain. The ability of apcin to block mitotic exit is synergistically amplified by co-addition of tosyl-l-arginine methyl ester, a small molecule that blocks the APC/C-Cdc20 interaction. This work suggests that simultaneous disruption of multiple, weak protein-protein interactions is an effective approach for inactivating a protein machine.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The substrate-binding domain of CDC20 is chemically tractable.
“suggesting that this domain is chemically tractable 62 .”
From Targeted protein degradation: expanding the toolbox (2019) · cites this paper as [62]
A weak small-molecule ligand that binds the substrate-binding domain of CDC20 was previously reported.
“Additionally, a weak small-molecule ligand that binds the substrate-binding domain of CDC20 was previously reported, suggesting that this domain is chemically tractable 62 .”
From Targeted protein degradation: expanding the toolbox (2019) · cites this paper as [62]
Substrate competitors with CDC20 block mitotic exit and induce tumour cell death.
“Substrate competitors with CDC20 block mitotic exit and induce tumour cell death 62 ,”
From Targeted protein degradation: expanding the toolbox (2019) · cites this paper as [62]
Apcin binds at the CDC20 site and inhibits ubiquitylation of D-box-containing substrates.
“apcin, a small molecule that binds at the same CDC20 site, inhibits the ubiquitylation of D-box-containing substrates 62 .”
From Targeted protein degradation: expanding the toolbox (2019) · cites this paper as [62]
Apcin binds CDC20 with low-micromolar affinity and occupies the D-box binding site.
“apcin, that binds CDC20 with low-micromolar affinity occupies the D-box binding site of the ligase”
From Targeted protein degradation: expanding the toolbox (2019) · cites this paper as [62]
A pocket at the side of the WDR domain of the APC-co-activating E3 ligases CDC20 and FZR1 is exploited by the chemical inhibitor apcin and by substrate peptides.
“A pocket at the side of the WDR domain of the APC-co-activating E3 ligases CDC20 and FZR1 is exploited by the chemical inhibitor apcin (yellow) and by substrate peptides (red) 62 .”
From Targeted protein degradation: expanding the toolbox (2019) · cites this paper as [62]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
The citation lists haven’t been fetched yet
References 41 · Cited by 257
- Authors
- Sackton, K. L., Dimova, N., Zeng, X., Tian, W., Zhang, M., Sackton, T. B., Meaders, J., Pfaff, K. L., Sigoillot, F., Yu, H., Luo, X., & King, R. W.
- Affiliations
- Harvard University (US)
- Howard Hughes Medical Institute (US)
- The University of Texas Southwestern Medical Center (US)
- Corresponding author
- King, Randall W.
- ORCID
- Venue
- Nature
- Published
- 2014-08-24
- Volume
- 514
- Issue
- 7524
- Pages
- 646-649
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC4214887
- OpenAlex
- W1988852424
- Cited by
- 257
- References
- 41
- Citations by year
- 2026: 14 · 2025: 22 · 2024: 19 · 2023: 14 · 2022: 21 · 2021: 31 · 2020: 36 · 2019: 24 · 2018: 15 · 2017: 22 · 2016: 25 · 2015: 12 · 2014: 2
- FWCI
- 10.30
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Funders
- Howard Hughes Medical Institute
- National Institute of General Medical Sciences (R56GM066492, R01GM066492, GM085004, GM066492, R01GM085004)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Microtubule and mitosis dynamics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Ubiquitin and proteasome pathways
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Keywords
- anaphase-promoting complex, CDC20, mitotic exit, protein-protein interaction inhibitors, ubiquitin ligase, D-box, WD40 domain, proteasome, securin, cyclin B1, synergistic inhibition, cancer therapy, ubiquitination
- MeSH terms
- Binding Sites, Carbamates, Diamines, Drug Synergism, Mitosis, Protein Binding, Tosylarginine Methyl Ester, Cell Death, Crystallography, X-Ray, Ubiquitination, Proteolysis, Anaphase-Promoting Complex-Cyclosome, Cdc20 Proteins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review